Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Allogene Therapeutics

Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2018 Unicorn

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

Valuation
$564M
Market cap · May/2026
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

5 investors on Allogene Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Pfizer
Two River
Vida Ventures
TPG
Perceptive Advisors

Global footprint

Where Allogene Therapeutics has talent and traffic

AI talent share
1.4% of workforce is AI talent
(3 of 208 staff)
Core AI10.48%
Other AI20.96%
Non-AI workforce20598.56%
Workforce by country
4 countries with
team presence
🇺🇸 United States98.7%
🇩🇪 Germany0.5%
🇨🇳 China0.5%
🇰🇷 South Korea0.5%
4 countries shown
Web traffic by country
19K monthly visits
across markets
🇺🇸 United States64.2%
🇨🇦 Canada12.1%
🇮🇳 India6.8%
🇬🇧 United Kingdom6.3%
🇪🇸 Spain5.3%
Top 5 markets shown

Patent intelligence

$64M patent portfolio · 71 active families

Estimated portfolio value
$64M
11.4% of market cap · 12.1× smaller than top peer BioNTech ($780M)
71 active patent families
Where Allogene Therapeutics innovates Molecular biologyCAR - Chimeric antigen receptorIMMUNOLOGIC CELLSCell biologyAntigen receptors

Where Allogene Therapeutics concentrates vs peers

Each axis is a top-10 topic across Allogene Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Allogene Therapeutics's 3 investments and acquisitions.

Every disclosed deal where Allogene Therapeutics appeared as a backer or acquirer, 2021–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Allogene Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Allogene Therapeutics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Allogene Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Allogene Therapeutics

        An AI-synthesized read of the highest-engagement posts about Allogene Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Allogene Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles